Glycaemic Responses to a Food Intake Sequence Intervention in Free-living Elite Female Athletes

December 4, 2025 updated by: Universidade do Porto

Glycaemic Responses to a Food Intake Sequence Intervention Under Free-living Conditions in Elite Female Athletes

The goal of this clinical trial is to investigate the impact of a food intake sequence intervention under free-living conditions on glycaemic responses in elite female athletes. Specifically, the main questions it aims to answer are:

  1. Does consuming breakfast in different food intake sequences alter postprandial interstitial glucose responses?
  2. Does consuming a pre-exercise meal in different food intake sequences alter interstitial glucose responses during exercise?
  3. Does consuming the last meal of the day in different food intake sequences alter nocturnal interstitial glucose responses?

To address these questions, researchers will compare eating the dietary sources of rapidly absorbed carbohydrate (CHO) at the end (CHO-last meal pattern) or at the start (CHO-first meal pattern) of standardised mixed meals, at different times of day, in a randomised, counterbalanced, crossover design.

Participants will wear a blinded continuous glucose monitor (CGM) for 6 consecutive days during a training camp. Throughout the study, they will be provided with buffet meals, at the same time and location each day. Dietary intake will be ad libitum, except for breakfast and supper, for which participants will select a preferred composition (ingredients, preparation methods, portion sizes) to replicate across study days. In all ad libitum meals (i.e., lunch, snacks, and dinner), they will be asked to maintain their assigned food intake sequence.

  • On day 1, athletes will eat freely. An educational session on the study protocol and food sequence manipulation will be delivered, and informed consent, questionnaires, screening assessments, and CGM fitting will be completed. Data collected by the CGM during the first 24 hours will be disregarded due to sensor stabilisation. Hence, this period will serve for familiarisation only.
  • On days 2 and 3, one group will eat the last meal of the day (i.e., supper) in a CHO-last meal pattern, while the other will follow a CHO-first meal pattern; on days 3 and 4 one group will eat breakfast in a CHO-last meal pattern while the other will follow a CHO-first meal pattern.
  • On days 4 and 5 (supper) and 5 and 6 (breakfast), participants in each group will adhere to the alternate condition.

Concurrent data on potential confounding factors (e.g., dietary intake, physical activity, internal and external load during training sessions/competition, sleep quantity and quality, menstrual cycle phase/status) will be collected.

Due to the short camp duration, implementing a one-day washout period will not be feasible. Therefore, repeated measurements over two consecutive days per condition will be obtained to minimise carryover effects of the food intake sequence from prior meals on end-of-intervention data (the final 24 hours per condition), and to assess intraindividual consistency of outcomes at matched-times and standardised settings.

Glycaemic responses will be compared within-participant between food intake sequences using linear mixed models with random intercepts, to account for repeated measures, interindividual variability, and potential missing data.

Study Overview

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lisbon District
      • Oeiras, Lisbon District, Portugal, 1495-433
        • Cidade do Futebol

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adult (18-64 years old)
  • Women
  • Elite athletes (meeting training and performance caliber criteria ≥Tier 4; McKay et al., 2022)
  • Healthy (meeting the exclusion criteria for medical conditions)
  • Normal glucose tolerant according to the latest review standards of the American Diabetes Association (ElSayed et al., 2024): HbA1c <5.7%, fasting plasma glucose <5.6 mmol/L (100 mg/dL), or 2-h plasma glucose <7.8 mmol/L (140 mg/dL) during a 75-g OGTT
  • Able and willing to provide informed consent and safely comply with study procedures

Exclusion Criteria:

  • Any medical condition or behaviour deemed either to pose undue personal risk to the participant or introduce bias into the experiment (e.g. pregnancy, alcohol or substance abuse; any condition affecting the glucose and lipid metabolism or appetite, reviewed on a case by case basis)
  • Any reported medication or supplementation that may interfere with the glucose metabolism (e.g., acarbose, aspirin, berberine, insulin, metformin, semaglutide, sulfonylureas, thiazide diuretics, thiazolidinediones, vitamin C). Other medication and supplementation will be reviewed on a case by case basis.
  • Recent change in body mass (± 2 kg in the last 2 months)
  • Smoking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CL - CF
The interventions (carbohydrate-last meal pattern (CL) or carbohydrate-first meal pattern (CF)) will be delivered in random order. If participants are allocated to this study arm, they will receive the CL on the first 2 days and the CF on the next 2 days of the study period.

Participants will consume the main dietary sources of protein, fat, fibre and/or polyphenols before the main dietary sources of simple carbohydrate in the standardised test-meals (breakfast and supper) and will be encouraged to maintain this food intake sequence in the remaining meals of the day.

Participants will be instructed to consume lunch and dinner within 30 min, and breakfast and supper within 15 min at a comfortable pace, without intervals between the carbohydrate and non-carbohydrate-rich meal components.

Other Names:
  • CL
  • CHO-last

Participants will consume the main dietary sources of protein, fat, fibre and/or polyphenols after the main dietary sources of simple carbohydrate in the standardised test-meals (breakfast and supper) and will be encouraged to maintain this food intake sequence in the remaining meals of the day.

Participants will be instructed to consume lunch and dinner within 30 min, and breakfast and supper within 15 min at a comfortable pace, without intervals between the carbohydrate and non-carbohydrate-rich meal components.

Other Names:
  • CF
  • CHO-first
Active Comparator: CF - CL
The interventions (carbohydrate-last meal pattern (CL) or carbohydrate-first meal pattern (CF)) will be delivered in random order. If participants are allocated to this study arm, they will receive the CF on the first 2 days and the CL on the next 2 days of the study period.

Participants will consume the main dietary sources of protein, fat, fibre and/or polyphenols before the main dietary sources of simple carbohydrate in the standardised test-meals (breakfast and supper) and will be encouraged to maintain this food intake sequence in the remaining meals of the day.

Participants will be instructed to consume lunch and dinner within 30 min, and breakfast and supper within 15 min at a comfortable pace, without intervals between the carbohydrate and non-carbohydrate-rich meal components.

Other Names:
  • CL
  • CHO-last

Participants will consume the main dietary sources of protein, fat, fibre and/or polyphenols after the main dietary sources of simple carbohydrate in the standardised test-meals (breakfast and supper) and will be encouraged to maintain this food intake sequence in the remaining meals of the day.

Participants will be instructed to consume lunch and dinner within 30 min, and breakfast and supper within 15 min at a comfortable pace, without intervals between the carbohydrate and non-carbohydrate-rich meal components.

Other Names:
  • CF
  • CHO-first

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incremental interstitial glucose peak after a standardised test meal
Time Frame: 0-120 minutes following a standardised test meal
Difference between CHO-last and CHO-first meal patterns in the incremental interstitial glucose peak (mmol/L) adjusted for baseline, following standardised breakfasts (independent of and coinciding with subsequent exercise) and the end-of-intervention (days 3 and 5) standardised supper, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
0-120 minutes following a standardised test meal

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incremental area under the interstitial glucose curve after a standardised test meal
Time Frame: 0-120 minutes following a standardised test meal
Difference between CHO-last and CHO-first meal patterns in the incremental area under the interstitial glucose curve (mmol/L x min) adjusted for baseline, following standardised breakfasts (independent of and coinciding with subsequent exercise) and the end-of-intervention (days 3 and 5) standardised supper, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
0-120 minutes following a standardised test meal
Time-to-peak interstitial glucose after a standardised test meal
Time Frame: 0-120 minutes following a standardised test meal
Difference between CHO-last and CHO-first meal patterns in the time-to-peak interstitial glucose (minutes), following standardised breakfasts (independent of and coinciding with subsequent exercise) and the end-of-intervention (days 3 and 5) standardised supper, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
0-120 minutes following a standardised test meal
Time out of interstitial glucose range after a standardised test meal
Time Frame: 0-180 minutes following a standardised test meal
Difference between CHO-last and CHO-first meal patterns in the time spent >7.8 mmol/L and time <3.9 mmol/L (%), following standardised breakfasts (independent of and coinciding with subsequent exercise) and the end-of-intervention (days 3 and 5) standardised supper, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
0-180 minutes following a standardised test meal
Interstitial glucose dip after a standardised test meal
Time Frame: 0-180 minutes following a standardised test meal
Difference between CHO-last and CHO-first meal patterns in the 2-3-hour interstitial glucose dip (mmol/L), following standardised breakfasts not coinciding with subsequent exercise, and the end-of-intervention (days 3 and 5) standardised supper, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
0-180 minutes following a standardised test meal
Interstitial glucose concentrations during specific activities
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the mean interstitial glucose concentrations (mmol/L) across 15-minute averages and adjusted for baseline where relevant, during the following periods: after standardised breakfasts (independent of and coinciding with exercise); after the end-of-intervention (days 3 and 5) standardised supper, during exercise not coinciding with postprandial periods, during evening sleep, and during daytime rest, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
24 hours
Within-day standard deviation of interstitial glucose
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the 24-hour standard deviation (SD) of interstitial glucose concentrations during the end-of-intervention monitoring period (days 3 and 5), assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ sensor).
24 hours
Within-day coefficient of variation of interstitial glucose
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the 24-hour coefficient of variation (%) of interstitial glucose concentrations during the end-of-intervention monitoring period (days 3 and 5), assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ sensor).
24 hours
Mean amplitude of glycaemic excursions (MAGE)
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the mean amplitude of glycaemic excursions (MAGE) during the end-of-intervention monitoring period (days 3 and 5), assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ sensor).
24 hours
Large amplitude of glycaemic excursions (LAGE)
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the large amplitude of glycaemic excursions (LAGE) during the end-of-intervention monitoring period (days 3 and 5), assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ sensor).
24 hours
Within-day time out of interstitial glucose range
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the time spent >7.8 mmol/L and <3.9 mmol/L (%) over 24 hours during the end-of-intervention monitoring period (days 3 and 5), assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ sensor).
24 hours
Between-day glycaemic variability
Time Frame: 24 hours
Difference between CHO-last and CHO-first meal patterns in the mean of daily differences (MODD) of interstitial glucose responses at matched clock times, assessed using a blinded continuous glucose monitoring system (Freestyle Libre Pro IQ).
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rita Giro, Faculty of Nutrition and Food Sciences of the University of Porto (FCNAUP); FPF Academy, Federação Portuguesa de Futebol

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 24, 2025

Primary Completion (Actual)

November 29, 2025

Study Completion (Actual)

November 29, 2025

Study Registration Dates

First Submitted

November 14, 2025

First Submitted That Met QC Criteria

November 21, 2025

First Posted (Estimated)

November 25, 2025

Study Record Updates

Last Update Posted (Actual)

December 5, 2025

Last Update Submitted That Met QC Criteria

December 4, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FOODSEQ-GRFA
  • 2022.12954.BD (Other Grant/Funding Number: Fundação para a Ciência e Tecnologia)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymised IPD will be made available upon reasonable request directed to the corresponding author.

IPD Sharing Time Frame

IPD will become accessible following the publication of all study findings.

IPD Sharing Access Criteria

IPD will be made available to researchers with legitimate scientific purposes (such as systematic reviews or meta-analyses).

IPD Sharing Supporting Information Type

  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Carbohydrate-last meal pattern

Subscribe